{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:18:18Z","timestamp":1786997898240,"version":"build-2736575974"},"reference-count":57,"publisher":"Elsevier BV","issue":"47","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["P01AI112524"],"award-info":[{"award-number":["P01AI112524"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.vaccine.2021.10.042","type":"journal-article","created":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T09:43:37Z","timestamp":1635155017000},"page":"6817-6828","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Coexpression of respiratory syncytial virus (RSV) fusion (F) protein and attachment glycoprotein (G) in a vesicular stomatitis virus (VSV) vector system provides synergistic effects against RSV infection in a cotton rat model"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1977-9707","authenticated-orcid":false,"given":"Kelsey A.","family":"Brakel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basavaraj","family":"Binjawadagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"French-Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2076-8853","authenticated-orcid":false,"given":"Mauria","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5420-0134","authenticated-orcid":false,"given":"Olivia","family":"Harder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7321-1878","authenticated-orcid":false,"given":"Yuanmei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianrong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4487-073X","authenticated-orcid":false,"given":"Stefan","family":"Niewiesk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2021.10.042_b0005","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa043951","article-title":"Respiratory syncytial virus infection in elderly and high-risk adults","volume":"352","author":"Falsey","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2021.10.042_b0010","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(10)60206-1","article-title":"Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis","volume":"375","author":"Nair","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2021.10.042_b0015","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.cimid.2007.07.008","article-title":"Human and bovine respiratory syncytial virus vaccine research and development","volume":"31","author":"Meyer","year":"2008","journal-title":"Comp Immunol Microbiol Infect Dis"},{"key":"10.1016\/j.vaccine.2021.10.042_b0020","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines7030059","article-title":"RSV vaccine based on rhabdoviral vector protects after single immunization","volume":"7","author":"Wilmschen","year":"2019","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2021.10.042_b0025","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.imlet.2012.12.005","article-title":"Non-propagating, recombinant vesicular stomatitis virus vectors encoding respiratory syncytial virus proteins generate potent humoral and cellular immunity against RSV and are protective in mice","volume":"150","author":"Johnson","year":"2013","journal-title":"Immunol Lett"},{"key":"10.1016\/j.vaccine.2021.10.042_b0030","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1128\/JVI.73.5.3723-3732.1999","article-title":"Attenuated Vesicular Stomatitis Viruses as Vaccine Vectors","volume":"73","author":"Roberts","year":"1999","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2021.10.042_b0035","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1006\/viro.2001.1212","article-title":"Live and killed rhabdovirus-based vectors as potential hepatitis C vaccines","volume":"292","author":"Siler","year":"2002","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2021.10.042_b0040","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.molmed.2004.03.003","article-title":"Vesicular stomatitis virus: Re-inventing the bullet","volume":"10","author":"Lichty","year":"2004","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.vaccine.2021.10.042_b0045","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jir349","article-title":"Recombinant vesicular stomatitis virus-based vaccines against Ebola and marburg virus infections","volume":"204","author":"Geisbert","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.10.042_b0050","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S1473-3099(17)30313-4","article-title":"Safety and immunogenicity of the rVSVG-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study","volume":"17","author":"Heppner","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2021.10.042_b0055","doi-asserted-by":"crossref","unstructured":"Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. the IMpact-RSV study group. Pediatrics 1998;102:531\u20137.","DOI":"10.1542\/peds.102.3.531"},{"key":"10.1016\/j.vaccine.2021.10.042_b0060","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/jpids\/piv087","article-title":"Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy native American infants: A phase 3 randomised double-blind placebo-controlled trial","volume":"5","author":"Hamdy","year":"2015","journal-title":"J Pediatric Infect Dis Soc"},{"key":"10.1016\/j.vaccine.2021.10.042_b0065","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1093\/infdis\/jiv281","article-title":"Effect of Preexisting Serum and Mucosal Antibody on Experimental Respiratory Syncytial Virus (RSV) Challenge and Infection of Adults","volume":"212","author":"Bagga","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.10.042_b0070","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.immuni.2017.01.010","article-title":"Respiratory Syncytial Virus Infects Regulatory B Cells in Human Neonates via Chemokine Receptor CX3CR1 and Promotes Lung Disease Severity","volume":"46","author":"Zhivaki","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2021.10.042_b0075","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.vaccine.2016.09.045","article-title":"Structural, antigenic and immunogenic features of respiratory syncytial virus glycoproteins relevant for vaccine development","volume":"35","author":"Melero","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.10.042_b0080","first-page":"83","article-title":"Structure and function of respiratory syncytial virus surface glycoproteins","volume":"372","author":"McLellan","year":"2013","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2021.10.042_b0085","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1093\/infdis\/jix489","article-title":"Prefusion F, postfusion F, G antibodies, and disease severity in infants and young children with acute respiratory syncytial virus infection","volume":"216","author":"Capella","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.10.042_b0090","first-page":"31","article-title":"Characterization of cotton rat (Sigmodon hispidus) eosinophils, including their response to respiratory syncytial virus infection","volume":"68","author":"Gia Green","year":"2018","journal-title":"Comp Med"},{"key":"10.1016\/j.vaccine.2021.10.042_b0095","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/oxfordjournals.aje.a118408","article-title":"A simple method of estimating fifty per cent endpoints","volume":"27","author":"Reed","year":"1938","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2021.10.042_b0100","doi-asserted-by":"crossref","first-page":"5122","DOI":"10.1128\/JVI.00019-14","article-title":"Heat Shock Protein 70 Enhances Mucosal Immunity against Human Norovirus When Coexpressed from a Vesicular Stomatitis Virus Vector","volume":"88","author":"Ma","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2021.10.042_b0105","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1128\/JVI.02332-10","article-title":"Vesicular Stomatitis Virus as a Vector To Deliver Virus-Like Particles of Human Norovirus: a New Vaccine Candidate against an Important Noncultivable Virus","volume":"85","author":"Ma","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2021.10.042_b0110","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02345-20","article-title":"Mucosal delivery of recombinant VSV vectors expressing envelope proteins of RSV induces protective immunity in cotton rats","volume":"95","author":"Binjawadagi","year":"2021","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2021.10.042_b0115","doi-asserted-by":"crossref","first-page":"8388","DOI":"10.1073\/pnas.92.18.8388","article-title":"Efficient recovery of infectious vesicular stomatitis virus entirely from cDNA clones","volume":"92","author":"Whelan","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2021.10.042_b0120","doi-asserted-by":"crossref","first-page":"9499","DOI":"10.1128\/JVI.01373-15","article-title":"Enhanced neutralizing antibody response induced by respiratory syncytial virus prefusion F protein expressed by a vaccine candidate","volume":"89","author":"Liang","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2021.10.042_b0125","first-page":"1","article-title":"Systematic comparison of 2A peptides for cloning multi-genes in a polycistronic vector","volume":"7","author":"Liu","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2021.10.042_b0130","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1128\/iai.42.1.81-87.1983","article-title":"Mechanisms of immunity to respiratory syncytial virus in cotton rats","volume":"42","author":"Prince","year":"1983","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2021.10.042_b0135","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/1743-422X-7-114","article-title":"A highly attenuated recombinant human respiratory syncytial virus lacking the G protein induces long-lasting protection in cotton rats","volume":"7","author":"Widjojoatmodjo","year":"2010","journal-title":"Virol J"},{"key":"10.1016\/j.vaccine.2021.10.042_b0140","doi-asserted-by":"crossref","first-page":"10710","DOI":"10.1128\/JVI.00986-09","article-title":"Respiratory syncytial virus grown in vero cells contains a truncated attachment protein that alters its infectivity and dependence on glycosaminoglycans","volume":"83","author":"Kwilas","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2021.10.042_b0145","doi-asserted-by":"crossref","first-page":"5625","DOI":"10.1073\/pnas.84.16.5625","article-title":"The G glycoprotein of human respiratory syncytial viruses of subgroups A and B: extensive sequence divergence between antigenically related proteins","volume":"84","author":"Johnson","year":"1987","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2021.10.042_b0150","doi-asserted-by":"crossref","first-page":"8193","DOI":"10.1128\/JVI.00133-15","article-title":"Nonglycosylated G-Protein Vaccine Protects against Homologous and Heterologous Respiratory Syncytial Virus (RSV) Challenge, while Glycosylated G Enhances RSV Lung Pathology and Cytokine Levels","volume":"89","author":"Fuentes","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2021.10.042_b0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009469","article-title":"The larger attachment glycoprotein of respiratory syncytial virus produced in primary human bronchial epithelial cultures reduces infectivity for cell lines","volume":"17","author":"King","year":"2021","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2021.10.042_b0160","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1128\/jvi.64.8.4007-4012.1990","article-title":"O glycosylation of glycoprotein G of human respiratory syncytial virus is specified within the divergent ectodomain","volume":"64","author":"Collins","year":"1990","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2021.10.042_b0165","doi-asserted-by":"crossref","first-page":"50852","DOI":"10.1371\/journal.pone.0050852","article-title":"Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats","volume":"7","author":"Smith","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2021.10.042_b0170","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1099\/0022-1317-83-1-61","article-title":"Multiple glycosylated forms of the respiratory syncytial virus fusion protein are expressed in virus-infected cells","volume":"83","author":"Rixon","year":"2002","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2021.10.042_b0175","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1128\/JVI.00560-17","article-title":"Parainfluenza Virus 5 Expressing Wild-Type or Prefusion Respiratory Syncytial Virus (RSV) Fusion Protein Protects Mice and Cotton Rats from RSV Challenge","volume":"91","author":"Phan","year":"2017","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2021.10.042_b0180","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1046\/j.1365-2249.1998.00650.x","article-title":"The immunostimulating complex (ISCOM) is an efficient mucosal delivery system for respiratory syncytial virus (RSV) envelope antigens inducing high local and systemic antibody responses","volume":"113","author":"Hu","year":"1998","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.vaccine.2021.10.042_b0185","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.204.Supp.245.26","article-title":"Safety, immunogenicity, and protective efficacy of a recombinant vaccine against RSV: evidence from murine and bovine models","volume":"204","author":"Diaz","year":"2020","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2021.10.042_b0190","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1128\/CVI.00250-09","article-title":"Intranasal immunization of mice with a bovine respiratory syncytial virus vaccine induces superior immunity and protection compared to those by subcutaneous delivery or combinations of intranasal and subcutaneous prime-boost strategies","volume":"17","author":"Mapletoft","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2021.10.042_b0195","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1038\/nm1213","article-title":"Mucosal immunity and vaccines","volume":"11","author":"Holmgren","year":"2005","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2021.10.042_b0200","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nri1777","article-title":"Mucosal vaccines: The promise and the challenge","volume":"6","author":"Neutra","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2021.10.042_b0205","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1016\/j.vaccine.2018.02.110","article-title":"A novel method for strict intranasal delivery of non-replicating RSV vaccines in cotton rats and non-human primates","volume":"36","author":"Citron","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.10.042_b0210","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1080\/21645515.2015.1114195","article-title":"Induction of mucosal immunity through systemic immunization: Phantom or reality?","volume":"12","author":"Su","year":"2016","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.vaccine.2021.10.042_b0215","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1128\/CVI.00214-16","article-title":"Parenteral vaccination can be an effective means of inducing protective mucosal responses","volume":"23","author":"Clements","year":"2016","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2021.10.042_b0220","first-page":"543","article-title":"Risk of primary infection and reinfection with respiratory syncytial virus","volume":"140","author":"Glezen","year":"1986","journal-title":"Am J Dis Child"},{"key":"10.1016\/j.vaccine.2021.10.042_b0225","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1056\/NEJM197903083001004","article-title":"Respiratory-syncytial-virus infections, reinfections and immunity","volume":"300","author":"Henderson","year":"1979","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2021.10.042_b0230","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jcv.2007.10.024","article-title":"Respiratory syncytial virus (RSV) vaccines-Two steps back for one leap forward","volume":"41","author":"Power","year":"2008","journal-title":"J Clin Virol"},{"key":"10.1016\/j.vaccine.2021.10.042_b0235","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1093\/infdis\/163.4.693","article-title":"Immunity to and frequency of reinfection with respiratory syncytial virus","volume":"163","author":"Hall","year":"1991","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.10.042_b0240","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1126\/science.1234914","article-title":"Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody","volume":"340","author":"McLellan","year":"2013","journal-title":"Science (80-)"},{"key":"10.1016\/j.vaccine.2021.10.042_b0245","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1073\/pnas.1115941109","article-title":"Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention","volume":"109","author":"Magro","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2021.10.042_b0250","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac4241","article-title":"Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera","volume":"7","author":"Ngwuta","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2021.10.042_b0255","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1126\/science.1243283","article-title":"Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus","volume":"342","author":"McLellan","year":"2013","journal-title":"Science (80-)"},{"key":"10.1016\/j.vaccine.2021.10.042_b0260","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1093\/infdis\/jix503","article-title":"An adjuvanted, postfusion F protein-based vaccine did not prevent respiratory syncytial virus illness in older adults","volume":"216","author":"Falloon","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.10.042_b0265","doi-asserted-by":"crossref","first-page":"9619","DOI":"10.1073\/pnas.1106536108","article-title":"Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers","volume":"108","author":"Swanson","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2021.10.042_b0270","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1128\/CVI.00720-15","article-title":"Novel respiratory syncytial virus-like particle vaccine composed of the postfusion and prefusion conformations of the F glycoprotein","volume":"23","author":"Cimica","year":"2016","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2021.10.042_b0275","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1128\/JVI.02043-18","article-title":"Effects of alterations to the CX3C motif and secreted form of human respiratory syncytial virus (RSV) G protein on immune responses to a parainfluenza virus vector expressing the RSV G protein","volume":"93","author":"Liang","year":"2019","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2021.10.042_b0280","doi-asserted-by":"crossref","first-page":"10022","DOI":"10.1128\/JVI.01196-16","article-title":"Packaging and prefusion stabilization separately and additively increase the quantity and quality of respiratory syncytial virus (RSV)-neutralizing antibodies induced by an RSV fusion protein expressed by a parainfluenza virus vector","volume":"90","author":"Liang","year":"2016","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2021.10.042_b0285","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1086\/315859","article-title":"Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy","volume":"182","author":"Wright","year":"2000","journal-title":"J Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21013748?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21013748?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:03:22Z","timestamp":1759403002000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21013748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":57,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S0264410X21013748"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.10.042","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Coexpression of respiratory syncytial virus (RSV) fusion (F) protein and attachment glycoprotein (G) in a vesicular stomatitis virus (VSV) vector system provides synergistic effects against RSV infection in a cotton rat model","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.10.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}